该行将长城汽车2025至2027年净盈利预测分别下调2%、5%及4%，反映新车型推出以及海外渠道开拓， 提升销售费用预期，同时海外业务占比增加，令公司税率有所上升；目标价由26港元降至24港元，评 级"增持"。 招商证券国际发表报告指，长城汽车第三季业绩低于预期，受俄罗斯报费用递延、汇兑及海外税率扰 动，但高端品牌魏明年指引乐观，出口业务今年明年有望强劲增长。报告指，长城汽车第三季实现营业 总收入612.5亿元，按年和按季分别增长20.5%和+17.1%，略低于市场预测的634亿，但符合该行预期。 汽车销量35.36万辆，按年和按季分别增长20.2%和+13%，增长强劲。对应单车收入17.32万元，按年和 按季分别增长9.3%和3%，中高端车占比提升。 ...

Core Viewpoint - The report from China Merchants Securities International indicates a downward revision of Great Wall Motors' (02333) earnings forecasts for 2025-2027 by 2%, 5%, and 4% respectively, due to increased sales expense predictions from new model launches and overseas channel expansion [1] Group 1: Earnings Forecasts - Great Wall Motors' earnings estimates for 2025, 2026, and 2027 have been reduced by 2%, 5%, and 4% respectively [1] - The adjustments reflect anticipated increases in sales expenses linked to new model introductions and the expansion of overseas channels [1] Group 2: Target Price and Rating - The target price for Great Wall Motors has been lowered by 8%, from HKD 26 to HKD 24 [1] - The rating remains "Buy" despite the downward revision [1] Group 3: Profit Influences - The company's third-quarter profits were impacted by multiple factors, including deferred expenses in Russia, foreign exchange fluctuations, and disturbances in overseas tax rates [1] Group 4: Brand and Export Outlook - The high-end brand "WEY" is expected to have an optimistic guidance for next year, aiming to challenge a monthly delivery of 60,000 units by 2026 [1] - The export business is projected to see strong growth, with an expected 500,000 units exported this year and a growth rate of no less than 20% in 2026 [1] - The European market is anticipated to see the launch of the EC15 model in the second quarter of 2026 to explore new market opportunities [1]

Core Viewpoint - The report from China Merchants Securities International indicates a downward revision of Great Wall Motors' (601633)(02333) earnings forecasts for 2025-2027 by 2%/5%/4%, reflecting increased sales expenses due to new model launches and overseas channel expansion, alongside a rising tax rate due to a higher proportion of overseas business. The target price has been reduced by 8% from HKD 26 to HKD 24, while maintaining a "Buy" rating [1] Group 1 - The group has faced multiple factors that negatively impacted third-quarter profits, including deferred expenses in Russia, foreign exchange fluctuations, and disturbances in overseas tax rates [1] - The high-end brand "WEY" has optimistic guidance for next year, aiming to challenge a monthly delivery of 60,000 units by 2026 [1] - Export business is expected to see strong growth, with the group anticipating exports to reach 500,000 units this year, and a growth rate of no less than 20% in 2026 [1] Group 2 - The European market is projected to see the launch of the EC15 model in the second quarter of 2026, aimed at expanding into new markets [1]

Group 1 - Hong Kong Stock Exchange data shows that on October 27, shareholders of Longfor Properties (06968) transferred shares from Deutsche Bank to China Merchants Securities Hong Kong, with a transfer market value of HKD 14.0646 million, accounting for 10.98% [1] - Longfor Properties reported that the group, along with its joint ventures and associates, achieved a contract sales amount of approximately RMB 4.0524 billion from January to September 2025, representing a year-on-year decrease of 0.15% [1]

Group 1 - The core point of the article highlights that on October 27, Hong Kong Dragon Real Estate (06968) transferred shares from Deutsche Bank to China Merchants Securities Hong Kong, with a market value of HKD 14.0646 million, accounting for 10.98% of the total shares [1] - Hong Kong Dragon Real Estate reported that the group, along with its joint ventures and associates, achieved a contract sales amount of approximately RMB 4.0524 billion from January to September 2025, representing a year-on-year decrease of 0.15% [1]

招商证券研报指出，预计三季报非金融A股盈利增速在较低基数背景下有望边际改善。大类行业中盈利 增速较高的行业预计主要集中在信息技术、中游制造业；上游资源品和医疗保健业绩降幅有望较中报收 窄，金融地产和消费服务相对承压。重点关注业绩有望延续较高增速的信息技术（通信设备、半导体、 消费电子、游戏、计算机设备等；持续复苏的中高端制造业（汽车零部件、电池、光伏设备、工程机 械、航天装备等）；低位修复的资源品和医药生物（钢铁、有色金属、化学制药等）。 ...

"从延长产业链到切入新赛道，并购重组已然成为上市公司实现高质量发展的'助推器'。"近日，招商证 券投资银行委员会并购业务部负责人王大为在接受证券时报记者采访时表示，当前并购业务的机遇主要 来自政策红利与产业升级的共振。 中小市值企业并购领跑 自去年9月"并购六条"实施以来，全市场新增重大资产重组交易超过200单。政策工具创新也在释放市场 活力，已有案例显示，股份对价分期支付、简易审核程序等机制显著提升了交易效率，特别是市值超百 亿元且信息披露优质的公司享受到了审核流程精简的红利。 在王大为看来，当前A股并购交易的驱动因素主要有三类：一是战略转型，传统企业通过并购切入新赛 道；二是产业链延伸，上市公司通过横向或纵向整合强化核心竞争力；三是培育第二增长曲线，通过注 入优质资产拓展盈利增长点。 根据公开市场数据，按证监会二级行业统计，计算机、通信和其他电子设备制造业上市公司的重大资产 重组数量居于首位。不同规模的上市公司均有参与，但中小型市值企业（20亿—120亿元）表现得尤为 活跃，"因为既有扩张需求，又具备灵活决策机制"。 基于实操经验，王大为还勾勒了"最受买方青睐的资产"画像——首先，在行业属性上，高技术装备 ...

Core Viewpoint - Jiangxi Institute of Biological Products Inc. (referred to as "Jiangxi Biological") has submitted a prospectus to the Hong Kong Stock Exchange for an IPO, marking its second attempt after a previous application lapsed in April 2025 [2]. Business Overview - Jiangxi Biological is the largest provider and exporter of human tetanus antitoxin (human TAT) in China and operates a fully integrated antiserum platform with over 50 years of expertise in research, production, and sales [6][8]. - The company's human TAT is included in the national Class A medical insurance list and the national essential drug list, providing it with a high level of market recognition and full insurance reimbursement advantages [6]. - Jiangxi Biological has a global sales and distribution network covering over 23,500 medical institutions in China, including more than 1,500 tertiary medical institutions [6]. Product Portfolio - In addition to human TAT, Jiangxi Biological's product offerings include veterinary tetanus antitoxin, equine serum gonadotropin (PMSG), and various hormone drugs for PMSG treatment [6]. - The company is developing innovative products targeting high-potential markets, including human antivenom serum and equine rabies immunoglobulin F(ab')2 [6]. Shareholder Structure - Prior to the IPO, the shareholder structure shows that Ms. Jing Yue holds a combined 76.64% stake through Hainan Zhizheng and Qianhai Tianzheng [9][10]. Board of Directors and Management - The board consists of 9 members, including 4 executive directors led by Ms. Jing Yue as the chairperson and Mr. Yao Xiaodong as the general manager [13][14][15]. Financial Performance - Jiangxi Biological's revenue for the years 2022, 2023, 2024, and the first half of 2025 were RMB 141.96 million, RMB 198.02 million, RMB 220.76 million, and RMB 99.70 million respectively, with corresponding net profits of RMB 26.47 million, RMB 55.48 million, RMB 75.14 million, and RMB 36.84 million [16]. IPO Advisory Team - The IPO advisory team includes CICC and CMB International as joint sponsors, with Deloitte as the auditor [18].

消息面上，券商三季报陆续披露，中信证券第三季度实现营业收入227.8亿元，同比增长55.7%，环比增 长49.1%，归母净利润94.4亿元，同比增长51.5%，环比增长31.6%；东方财富第三季度实现营业总收入 47亿元，同比增长101%，归母净利润35亿元，同比增长78%。此外，2025金融街论坛年会将于10月27 日至30日在北京金融街举行，中国人民银行行长潘功胜、金融监督管理总局局长李云泽、中国证监会主 席吴清将出席年会并作主题演讲。 中航证券指出，伴随资本市场扩容与交投活跃度提升，券商板块正迎来重要的战略配置机遇。当前A股 市值已突破100万亿元，为券商各业务线打开了广阔的长期成长空间。市场交易活跃度显著改善，前三 季度全市场日均成交额同比大幅增长，叠加两融余额持续攀升并创下新高，共同强化了券商板块的业绩 确定性。市场活跃的势能有望延续，为券商业绩的持续增长提供坚实支撑。展望全年，资本市场预计将 保持稳步向上趋势，业绩增长的可持续性有望增强，板块具备估值修复潜力。 中资券商股集体上涨，截至发稿，中金公司(03908)涨4.06%，报23.58港元；招商证券(06099)涨3.7%， 报16.8港元；东 ...

Group 1 - Chinese brokerage stocks collectively rose, with notable increases in shares of major firms such as CITIC Securities, which rose by 4.06% to HKD 23.58, and Orient Securities, which increased by 3.75% to HKD 8.03 [1] - The third-quarter financial reports of brokerages revealed significant growth, with CITIC Securities reporting a revenue of CNY 22.78 billion, a year-on-year increase of 55.7%, and a net profit of CNY 9.44 billion, up 51.5% year-on-year [1] - Orient Wealth reported a total revenue of CNY 4.7 billion for the third quarter, marking a 101% year-on-year increase, with a net profit of CNY 3.5 billion, up 78% year-on-year [1] Group 2 - The brokerage sector is experiencing a strategic configuration opportunity due to the expansion of the capital market and increased trading activity, with the A-share market capitalization surpassing CNY 100 trillion [2] - The average daily trading volume in the market has significantly improved, with a notable year-on-year increase in the first three quarters, alongside a continuous rise in margin financing balances [2] - The capital market is expected to maintain a steady upward trend, enhancing the sustainability of performance growth in the brokerage sector, which possesses potential for valuation recovery [2]